Hanmi Pharmaceutical's independently developed glucagon-like peptide (GLP)-1 class obesity and metabolic disease therapy "Efpeglenatide" and the diabetes combination therapy "Dafaron family" are set to be exported to Mexico.
Hanmi Pharmaceutical said on the 28th that it signed an exclusive distribution agreement with Mexican drugmaker Sanfer for Efpeglenatide and the Dafaron family, among others. The contract is worth about 65.86119 billion won, and the term runs for 10 years from Jan. 26, 2026, to Jan. 26, 2036. Detailed payment terms, including any upfront payment, were not disclosed.
Under the deal, Hanmi Pharmaceutical will supply finished goods of Efpeglenatide and the Dafaron family (Dafaron tablets and Dafaron Duo extended-release tablets), Hanmi's flagship diabetes lineup. Sanfer will handle approval, marketing, distribution and sales in Mexico.
According to the company, Mexico is a representative high-obesity country, with an obesity prevalence of 36.86%. The diabetes prevalence is known to be 16.4%. Founded in 1941, Sanfer is Mexico's largest private pharmaceutical company, with a strong sales and distribution network across Latin America and its own research and development capabilities.
With this agreement, the two companies plan to gradually expand cooperation on Efpeglenatide and metabolic disease therapies overall. Over the mid to long term, they will also discuss additional product introductions and joint marketing strategies in close detail.
Ricardo Amtmann, CEO of Sanfer, said, "In Mexico, about 34.6% of household expenditure goes to medical costs, so easing the medical burden and ensuring access to innovative therapies are key tasks," adding, "Hanmi Pharmaceutical's new obesity drug and diabetes lineup have the product capabilities to meet these conditions."
Park Jae-hyun, CEO of Hanmi Pharmaceutical, said, "This agreement is an important achievement that proves Hanmi's outstanding formulation technology and R&D competitiveness on the global stage."
Hanmi Pharmaceutical completed a marketing authorization application for Efpeglenatide with the Ministery of Food and Drug Safety in December last year. In September last year, it submitted a phase 3 clinical trial plan (IND) for combination therapy with an SGLT-2 inhibitor and metformin, winning approval on the 21st. The company is developing the drug with the goal of an obesity approval in the second half of this year and an additional diabetes indication in 2028.